Formulation Development Applications & Studies

31. A Holistic Approach To Understanding High And Low HEK293 Producer 4/4/2025

    Despite advancements in AAV-based gene therapy, key aspects of AAV biology and production remain unclear. Find out how researchers are exploring HEK293 subclones to identify traits that enhance viral vector yields.

32. 2D To 3D Transition Of Mesenchymal Stem Cell Expansion Process 4/4/2025

    Discover how transitioning from 2D to 3D culture methods enhances the scalability, yield, and quality of Mesenchymal Stem Cells (MSCs) for therapeutic applications to address critical manufacturing challenges.

33. Advantages Of Spray-Dried Mannitol In Roll Compaction 4/2/2025

    Pharmaceutical excipients like mannitol enhance formulation stability, flowability, and compressibility, which are crucial for robust tablets. Read how these properties improve patient compliance.

34. Rapid Walkaway Solution For Assessing Viability In Cancer Organoids 3/31/2025

    Assess anti-cancer compounds' effects on organoid size and morphology with colorectal cancer organoids as well as discover automated imaging and viability assays to streamline drug screening and aid early identification.

35. Matrigel Dome Assay And Drug Screening Of Colorectal Cancer Organoids 3/31/2025

    Using CRC organoids and bioprinting, explore the automation of dome assays to evaluate drug responses and delve into the insights from image-based end-point assays on the efficacy of anti-cancer treatments.

36. Unravelling Immunological Depths: Exploring Oxazolone-Induced Delayed-Type Hypersensitivity Model 3/28/2025

    Validating the oxazolone-induced DTH mouse model offers a critical platform for advancing the evaluation of therapeutic candidates for chronic inflammatory diseases, including atopic dermatitis.

37. A Pre-Clinical Study For Diet-Induced Obesity 3/28/2025

    Here, we look at the importance of using high-fat diet-induced obesity models to evaluate and compare the efficacy of anti-obesity and anti-diabetic treatments like rimonabant and liraglutide.

38. Enhancing mAb Processing With Protein A Membrane Chromatography For FIH Molecules 3/28/2025

    Our findings highlight this technology's potential in clinical development, providing greater flexibility, a smaller manufacturing footprint, and a more efficient purification process.

39. Rapid And Simple Aggregate Removal Of mAbs Using Competitive Binding On CEX 3/28/2025

    To ensure the safety, efficacy, and stability of monoclonal antibody therapies, it is crucial to understand the factors driving aggregation and implement effective strategies to mitigate its impact.

40. Therapeutic Effects Of An ALK5 Inhibitor In Preclinical Fibrosis Models 3/28/2025

    Our preclinical studies evaluating ALK5 inhibition in various mouse models of fibrosis have demonstrated differing degrees of therapeutic benefit, suggesting the potential for selective targeting.